Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
ClinicalTrials.gov Identifier:
NCT01404182
First received: July 26, 2011
Last updated: May 18, 2012
Last verified: May 2012

July 26, 2011
May 18, 2012
July 2011
August 2011   (final data collection date for primary outcome measure)
Post vaccination HI antibody titer [ Time Frame: 21-28 days following vaccination ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01404182 on ClinicalTrials.gov Archive Site
Incidence of adverse reactions [ Time Frame: 21-28 days following vaccination ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons
Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine (Trivalent, Seasonal, Active Ingredient Content: 15 μg HA/Strain/0.5 mL) in Adults and Elderly Persons

The purpose of this study is to determine the immunogenicity and tolerability of Fluval AB trivalent influenza vaccine in adults and elderly people.

Immunogenicity Objective:

To assess immunogenicity of a single intramuscular (IM) injection of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each), as measured by haemagglutination inhibition (HI) test.

Safety and Tolerability Objectives:

To evaluate safety and tolerability (incidence of adverse events) of a single intramuscular (IM) injection of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL).

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Influenza
Biological: Vaccination with Fluval AB influenza vaccine
Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
Other Names:
  • Influenza
  • Seasonal vaccine
  • Vaccination
  • Prevention
  • Influenza vaccine
  • Influenza in humans
Experimental: Influenza vaccination
Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
Intervention: Biological: Vaccination with Fluval AB influenza vaccine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
121
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults aged 18 to 60 years, elderly persons aged over 60 years, both sexes, mentally competent
  • Are in good health (as determined by vital signs and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study
  • Female volunteers aged 18-60 years (i.e. participants of childbearing potential) with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method or abstinence throughout the trial and not become pregnant for the duration of the study.
  • Capability of participants to understand and comply with planned study procedures
  • Participants aged above 18 years provide written informed consent prior to initiation of study procedures
  • Absence of existence of any exclusion criteria.

Exclusion Criteria:

  • Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to vaccination. Female subjects who are able to bear children but not willing to use an acceptable contraception method for the duration of the study.
  • Known hypersensitivity to eggs, chicken protein, thiomersal, formaldehyde, gentamycin, ciprofloxacin, neomycin or any other component of the vaccine
  • History of Guillain-Barré syndrome
  • History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine
  • Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure
  • Immunosuppressive therapy within the past 36 months
  • Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids
  • Receipt of immunostimulants,
  • Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within the past 3 months
  • Suspected or HIV, HBV or HCV infection
  • Acute disease and/or axillary temperature ≥37oC within the past 3 days
  • Vaccine therapy within the past 4 weeks
  • Influenza vaccination (any kind) within the past 6 months
  • Experimental drug therapy within the past 4 weeks
  • Concomitant participation in another clinical study
  • Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study
  • Past or current psychiatric disease of the volunteer that upon judgement of the investigator may have effect on the objective decision-making of the volunteer
  • Alcohol or drug abuse of the participant.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Hungary
 
NCT01404182
FluvalAB-H-YL2011, 2011-002158-30
No
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Not Provided
Principal Investigator: Ferenc Tamás, MD Family Doctor's Office Pilisvorosvar
Principal Investigator: László Sinka, MD Fourmed Gyogyhaz Kft.
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP